Cargando…

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid

MDR-TB patients treated with 6 months or more of delamanid had significantly lower likelihood of mortality http://ow.ly/HOv1d

Detalles Bibliográficos
Autores principales:	Wells, Charles D., Gupta, Rajesh, Hittel, Norbert, Geiter, Lawrence J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2015
Materias:	Agora
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416109/ https://www.ncbi.nlm.nih.gov/pubmed/25700385 http://dx.doi.org/10.1183/09031936.00176314

Ejemplares similares

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
por: Hafkin, Jeffrey, et al.
Publicado: (2017)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
por: Skripconoka, Vija, et al.
Publicado: (2013)

Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union
por: van der Werf, Marieke J., et al.
Publicado: (2017)

Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis
por: Tornheim, Jeffrey A., et al.
Publicado: (2022)

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
por: Tadolini, Marina, et al.
Publicado: (2016)

Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China
por: Lu, Peng, et al.
Publicado: (2017)

Numbers needed to treat to prevent tuberculosis
por: Matteelli, Alberto, et al.
Publicado: (2015)

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Mallikaarjun, Suresh, et al.
Publicado: (2020)

A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis
por: Gupta, Nitesh, et al.
Publicado: (2020)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
por: Szumowski, John D, et al.
Publicado: (2015)

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
por: Nimmo, Camus, et al.
Publicado: (2020)

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?
por: Ndjeka, Norbert, et al.
Publicado: (2020)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis
por: Akkerman, Onno W., et al.
Publicado: (2018)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Practices of therapeutic drug monitoring in tuberculosis: an international survey
por: Margineanu, Ioana, et al.
Publicado: (2022)

On tuberculosis and COVID-19 co-infection
por: Tadolini, Marina, et al.
Publicado: (2020)

Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan
por: Lee, Meng-Rui, et al.
Publicado: (2017)

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review
por: Assefa, Yibeltal, et al.
Publicado: (2018)

Global reporting on tuberculosis preventive treatment among contacts
por: Falzon, Dennis, et al.
Publicado: (2022)

Screening for tuberculosis among high-risk groups attending London emergency departments: a prospective observational study
por: Gupta, Rishi K., et al.
Publicado: (2021)

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Wang, Xiaofeng, et al.
Publicado: (2020)

Tuberculosis prevention must integrate technological and basic care innovation
por: Mason, Paul H., et al.
Publicado: (2016)

The potential impact of COVID-19-related disruption on tuberculosis burden
por: McQuaid, C. Finn, et al.
Publicado: (2020)

Insight into the impact of the COVID-19 epidemic on tuberculosis burden in China
por: Chen, Hongguang, et al.
Publicado: (2020)

Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe
por: Nikolayevskyy, Vladyslav, et al.
Publicado: (2021)

QIAreach QuantiFERON-TB for the diagnosis of Mycobacterium tuberculosis infection
por: Saluzzo, Francesca, et al.
Publicado: (2022)

Variation in policy and practice of adolescent tuberculosis management in the WHO European Region
por: Blok, Nick, et al.
Publicado: (2016)

The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region
por: Chiang, Chen-Yuan, et al.
Publicado: (2020)

Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study
por: Migliori, Giovanni Battista, et al.
Publicado: (2021)

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
por: Guglielmetti, Lorenzo, et al.
Publicado: (2022)

Arterial hypertension and the risk of severity and mortality of COVID-19
por: Leiva Sisnieguez, Carlos Enrique, et al.
Publicado: (2020)

Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience
por: Sinkou, Heorhi, et al.
Publicado: (2017)

Impact of the SARS-CoV-2 epidemic on tuberculosis treatment outcome in Northern Italy
por: Magro, Paola, et al.
Publicado: (2020)

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases
por: Tadolini, Marina, et al.
Publicado: (2020)

Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital
por: Stochino, Claudia, et al.
Publicado: (2020)

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally
por: Masini, Tiziana, et al.
Publicado: (2022)

Does a single Pseudomonas aeruginosa isolation predict COPD mortality?
por: Boutou, Afroditi K., et al.
Publicado: (2014)

Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion
por: Sotgiu, Giovanni, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_enq0n71dqua4tj0mq805703hrq